ArticleInfection and drug resistance2025
Risk Factors for Development and Mortality of Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Genomic characteristics and risk factor analysis of carbapenem-non-susceptible Pseudomonas aeruginosa causing bacteremia in a tertiary hospital (2014-2023).BMC microbiology · 2026Article
- Predictors of Mortality inPathogens (Basel, Switzerland) · 2026Review
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
- Genomic Epidemiology and Antimicrobial Resistance Analyses ofInfection and drug resistance · 2026Article
- Risk prediction of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Distribution and Antimicrobial Resistance Trends of Bloodstream Bacterial Isolates: A 10-year Single-Center Study in China.Infection and drug resistance · 2026Article
- The efficacy and safety of ceftazidime/avibactam or polymyxin B based regimens forFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Methods: A total of 112 patients with CRPA BSI and 112 patients with carbapenem-sensitive Results: In the past 7 years, 7480 blood samples of Conclusion: Chronic lung disease, transplantation, multi-organ failure, prior CRPA infection, and prior carbapenems exposure are independent risk factors for the development of CRPA bacteremia. Sepsis or septic shock increases 28-day mortality. To investigate the molecular mechanisms of carbapenem-resistance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.